This information sheet highlights key facts about Hepatitis B, including how it spreads, who is at risk, and steps for prevention and treatment. It emphasizes the importance of vaccination, routine testing, and early care to reduce transmission and prevent long-term liver damage.
This fact sheet addresses common questions about insurance coverage for viral hepatitis prevention and treatment services. It outlines coverage details for hepatitis A and B vaccinations, hepatitis B and C screenings, and treatments across various insurance types, including Medicaid, Medicare, and private plans.
Esta página web ofrece una descripción general de la hepatitis B, incluyendo sus causas, síntomas, diagnóstico y opciones de tratamiento. Se enfatiza la importancia de la vacunación para prevenir la propagación de la hepatitis B y reducir el riesgo de cáncer de hígado y otras complicaciones graves de salud.
This webpage provides an overview of hepatitis B, including its causes, symptoms, diagnosis, and treatment options. It emphasizes the importance of vaccination in preventing the spread of hepatitis B and reducing the risk of liver cancer and other serious health complications.
This infographic provides an overview of hepatitis B, detailing its transmission, symptoms, and prevention strategies.
This video promotes the hepatitis B birth dose as a critical first step in protecting newborns from lifelong infection and liver cancer. It emphasizes that most people with hepatitis B are unknowingly infected at birth and that early vaccination is safe, effective, and the world’s first anti-cancer vaccine.
This fact sheet presents key talking points emphasizing the critical importance of administering the hepatitis B vaccine birth dose to newborns.
This journal compares the effectiveness of Heplisav-B and standard hepatitis B vaccines as boosters for healthcare workers with low immunity to hepatitis B, measured by anti-HBs antibody levels. Results show that Heplisav-B offers a significantly higher seropositivity rate (99.4%) compared to the standard vaccine (92.7%).
This journal outlines best practices for engaging communities affected by chronic hepatitis B, emphasizing the importance of involving individuals with lived experiences in public health initiatives to improve diagnosis and treatment outcomes.
This report outlines progress toward eliminating mother-to-child transmission of hepatitis B virus (HBV) in the Americas from 2012 to 2022. It highlights improvements in vaccination coverage, including birth doses, but also notes coverage declines in some countries, which could hinder elimination goals. The report emphasizes the need for maintaining high vaccination rates, expanding hepatitis B testing for pregnant women, and ensuring timely treatment for newborns.
